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Background: Treatment with selective vitamin D receptor activators such as paricalcitol have been shown to exert
an anti-inflammatory effect in patients on hemodialysis, in addition to their action on mineral metabolism and
independently of parathyroid hormone (PTH) levels. The objective of this study was to evaluate the additional
antioxidant capacity of paricalcitol in a clinical setting.
Methods: The study included 19 patients with renal disease on hemodialysis, of whom peripheral blood was
obtained for analysis at baseline and three months after starting intravenous paricalcitol treatment. The following
oxidizing and inflammatory markers were quantified: malondialdehyde (MDA), nitrites and carbonyl groups,
indoleamine 2,3-dioxygenase (IDO), tumor necrosis factor alfa (TNF-α), interleukin-6 (IL-6), interleukin-18 (IL-18) and
C-reactive protein (CRP). Of the antioxidants and anti-inflammatory markers, superoxide dismutase (SOD), catalase,
reduced glutathione (GSH), thioredoxin, and interleukin-10 (IL-10) levels were obtained.
Results: Baseline levels of oxidation markers MDA, nitric oxide and protein carbonyl groups significantly decreased
after three months on paricalcitol treatment, while levels of GSH, thioredoxin, catalase and SOD activity significantly
increased. After paricalcitol treatment, levels of the inflammatory markers CRP, TNF-α, IL-6 and IL-18 were
significantly reduced in serum and the level of anti-inflammatory cytokine IL-10 was increased.
Conclusions: In renal patients undergoing hemodialysis, paricalcitol treatment significantly reduces oxidative stress
and inflammation, two well known factors leading to cardiovascular damage.
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Oxidative stress is defined as the loss of balance between
the generation of oxidants and the system’s antioxidant
activity, in favor of the former. The production of super-
oxide anion, a by-product of the respiratory chain from
which most free radicals derive, increases with the activ-
ity of NADPH oxidase in response to certain stimuli, in-
cluding proinflammatory mediators such as complement
component C5a, interleukins, tumor necrosis factor, bac-
terial molecules, endotoxins, etc. [1]. Maintenance of
this balance is crucial in biological systems, and cells are
endowed with a molecular defense system, including* Correspondence: mjizquierdo3@hotmail.com
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reproduction in any medium, provided the orantioxidant enzymes such as superoxide dismutase
(SOD), glutathione peroxidase and catalase, as well as
vitamins (A, C, and E) and reduced glutathione (GSH).
Nevertheless, some conditions or disease treatments
may have an effect on this finely controlled balance,
causing oxidative stress that exacerbates the patient’s
condition. Such is the case of renal patients on dialysis;
exposed to increased levels of oxidants due to their
uremia [2,3], they have an additional load on the
oxidative-inflammatory arm of this balance, caused by
bioincompatible systems, adjunctive treatments (erythro-
poiesis-stimulating agents, intravenous iron therapy) and
the antioxidant depletion caused by hemodialysis per se
[4]. Oxidative stress in these patients leads to a state of
malnutrition and accelerated cardiovascular disease
[5,6].al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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been previously studied, and dialysis treatment has been
shown to increase lipid peroxidation in cell membranes
and oxidation markers in the blood of treated patients
[7], leading to cardiovascular dysfunction. Likewise, the
characteristic apoptosis of peripheral blood leukocytes in
renal patients has been associated with oxidative stress
by depletion of intracellular thiol groups [8,9]. Given the
body of evidence linking pathophysiological dialysis
treatment with oxidative stress, which causes progressive
worsening of renal patients, including cardiovascular
morbidity and mortality [5,6], some authors have indi-
cated that antioxidant therapy should be a central pillar
of the preventive and curative treatment of renal disease
[10,11]. Increasing evidence shows the prevalent role of
vitamin D signaling pathways in redox homeostasis and
cardiovascular disease prevention [12-15]. Vitamin D re-
ceptor (VDR) is present in many organs and displays
pleiotropic effects; moreover, a recent clinical report
indicated that intravenous calcitriol, as a VDR agonist
(VDRA), reduces oxidative stress in hemodialysis
patients [13].
The purpose of this study was to assess the effects of
intravenous paricalcitol, a selective VDR agonist, on redox
homeostasis and antioxidant systems in hemodialysis
patients with secondary hyperparathyroidism (SHPT), as a
possible added benefit of its use in these patients.
Methods
This study was approved by the Clinical Research Ethics
Committee of Hospital General Yagüe (Burgos, Spain).
All the patients included were fully informed and gave
their written consent to participate. Eligible patients
were naïve to vitamin-D analogues or derivatives, had
undergone regular hemodialysis three times per week for
at least 12 months before the study started, and needed
treatment for SHPT, presenting PTH levels ≥ 300 pg/ml,
serum calcium ≥ 8 mg/dl and serum phosphorus ≤
5.5 mg/dl. Paricalcitol dosing depended upon the levels
of calcium, phosphorus and PTH. Patients presenting
with PTH levels ≥ 300 pg/ml, serum calcium ≤ 9.5 mg/dl
and serum phosphorus ≤ 4.5 mg/dl received 15 μg/week,
distributed in three hemodialysis sessions. Those with
PTH levels ≥ 300 pg/ml, serum calcium > 9.5 mg/dl and
serum phosphorus > 4.5 mg/dl received 7.5 μg/week, dis-
tributed in three hemodialysis sessions. Those partici-
pants who suffered infectious or inflammatory episodes
during the active phase of the study period, or who had
neoplasia, were excluded from data analysis, as were
those who needed transfusions or replacement of their
vascular access during the study. Other reasons for ex-
clusion were adverse effects leading to a reduction in the
paricalcitol dose or treatment suspension. In the case of
hyperphosphatemia, patients were treated with non-calcium binders and a controlled diet. Any concomitant
treatment the patients were receiving prior to this study
was maintained without variations.
Blood samples for baseline determinations were col-
lected from each patient after inclusion and just prior to
initiating paricalcitol treatment. A second sample was
taken at a follow-up visit after three months of receiving
paricalcitol. Extractions were performed on the day be-
tween dialysis treatments. The paricalcitol dosage for
each patient was calculated according to baseline cal-
cium, phosphorus and PTH levels. Paricalcitol doses
were maintained throughout the treatment period, and
were reduced only in the case of hypercalcemia or
hyperphosphatemia; however they could be increased if
SHPT persisted and electrolyte levels were adequate.
Whole blood was used for some measurements, using
heparin as anticoagulant; serum was separated following
a standard protocol.
Determination of inflammation markers in serum
The serum IL-6, IL-10, IL-18 and TNF-α levels were
quantified using ELISA kits (R&D Systems, Minneapolis,
USA). Serum CRP was measured using a high sensitivity
turbidimetric immunoassay (hs-CRP), calcium using
the calcium-o-cresolphthalein complexone method and
phosphorus using the phosphomolybdate method. All
were analyzed on a Roche/Hitachi Modular P analyzer
ACN 210 (Roche Diagnostics, Basel, Switzerland). IDO
activity was evaluated by measuring kynurenine in
plasma according to Alegre et al. [16]. Serum PTH was
quantified by electrochemiuminescence immunoassay,
using a Roche Elecsys 1010/2010 analyzer (Roche Diag-
nostics, Basel, Switzerland). Each sample was analyzed in
triplicate.
Analysis of oxidative stress-related parameters
SOD activity was quantified with the method developed
by McCord and Fridovich [17], based on the production
of superoxide radicals during the conversion of xanthine
to uric acid by xanthine oxidase, and the inhibition of
cytochrome c reduction. One unit of SOD activity was
defined as the amount of SOD that produces 50% inhib-
ition of cytochrome c reduction. Catalase activities were
assayed using the method described by Claibone [18].
Reduced GSH levels were measured in blood using the
protocol of Brigelius et al. [19] for glutathione-S-trans-
ferase. Plasma thioredoxin was determined with an
ELISA kit (TRX ELISA Kit, Redox Bioscience Inc.,
Japan), and malondialdehyde (MDA) was measured by
HPLC [20].
Protein oxidation was assessed with an estimation of
carbonyl groups formed using the protocol described by
Levine et al. [21]. Total protein concentration was deter-
mined by the Lowry method [22], using bovine albumin
Table 1 Effects of paricalcitol on SHPT and electrolyte
levels in our sample
N = 19 Paricalcitol P
value*Baseline values After 12 weeks
Ca, mg/dL 8.59 ± 0.58 9.44 ± 0.71 0.00026
P, mg/dL 4.25 ± 0.71 4.81 ± 1.11 0.0248
PTH, pg/mL 441 ± 221 205 ± 172 0.00014
Ca, calcium; P, phosphorus; PTH, parathyroid hormone. Data are mean ± SD.
Statistical significance assessed using Wilcoxon Signed Rank Test.
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to indirectly measure nitric oxide content, was per-
formed for nitrite quantification.
Statistical analysis
All data are reported as mean ± SD. Comparison be-
tween parameter values obtained before treatment and
three months after treatment initiation was performed
using the paired Wilcoxon test for comparisons, since
the sample size was too small for parametric tests. All
statistical analyses were performed using software envir-
onment R, version 2.14.0 (Developed by international R
project: http://www.r-project.org).
Results
The study included 19 renal patients on dialysis (15 male
and 4 female), between 42 and 78 years of age (mean 68
± 13.5), with two types of vascular access: arteriovenous
fistula (n= 14) or permanent internal jugular catheter
(n= 5). Etiology of kidney disease in our sample was dia-
betes mellitus (n= 2), nephrosclerosis (n= 12), polycystic
kidney disease (n= 1), and vasculitis (n= 4). All patients
received treatment with EPO alfa (mean dose 5842 ±
3610 U/week, SC) as an erythropoiesis-stimulating
agent; 52.6% of patients were already receiving intraven-
ous iron (5 mg/week) two months before initiating pari-
calcitol treatment and iron therapy was maintained at
the same dose throughout the study; 63.2% of patients
were taking statins to treat dyslipidemia, and 15.8% were
on angiotensin-converting enzyme (ACE) inhibitors II or
angiotensin receptor blockers (ARB). The dialysis vin-
tage had a median of 43.1 months (max. 120 - min.
12 months). Dialysis was performed for all patients using
a high-flux dialyzer with a polyethersulphone membrane
filter (Elisio 210H), with effective surface area 2.1 m²
and dialysis solution containing 1.25-1.5 mmol/l of cal-
cium. This dialysis protocol was maintained throughout
the study. All patients had received previous treatment
for SHPT: six had received calcium-chelating agents,
twelve other chelating agents and one calcimimetics.
Baseline oxidation and inflammation parameters were
similar in all patients.
Secondary hyperparathyroidism
The mean paricalcitol dose was 13.46 ± 3.98 μg/week
and all patients included in the final analysis received
paricalcitol for 12 weeks with no variations. All the
patients responded to treatment, and endpoint values
were compared to their baseline parameters. The
dose and treatment schedule were based on the patient’s
calculated requirements, as indicated in the Methods
section.
Baseline PTH, calcium and phosphorus levels are
shown for all the participants (Table 1). High baselinePTH levels were significantly decreased after 12 weeks
of treatment with paricalcitol, while both blood calcium
and phosphorus levels were increased.
Inflammation biomarkers
Interleukins in serum were measured in 13 patients. Par-
icalcitol significantly increased serum IL-10 levels. On
the other hand, inflammatory cytokine levels, including
IL-18, IL-6, and TNF-α were reduced after twelve weeks
of treatment (Table 2). The reduction rate in serum was
approximately 74%, 66%, and 53% for IL-18, IL-6, and
TNF-α, respectively. However, no differences were seen
in IDO activity as a result of the treatment.
Oxidative stress biomarkers
Compared to baseline values, increased antioxidant
concentrations were observed (Table 3), including the
enzymatic participants (SOD and catalase), and non-
enzymatic scavengers (GSH and thioredoxin). SOD,
catalase, GSH and thioredoxin levels in blood were
significantly higher: 3.74, 1.35, 1.77 and 1.65-fold the
baseline values. We determined the carbonyl groups
and MDA levels in plasma as parameters indicative of
protein and lipid oxidative damage and nitrites. As
shown in Table 3, all were found to be significantly
reduced after paricalcitol therapy.
Discussion
Our results suggest that treatment with paricalcitol, a
VDR selective activator, has antioxidant and anti-inflam-
matory effects in patients on hemodialysis. This poten-
tial effect could be very beneficial for these patients,
since they suffer redox imbalance due to the uremia
caused by their renal condition [2]. Many treatments
also induce oxidation and inflammation in hemodialysis
patients, including intravenous iron therapy, erythropoi-
esis-stimulating agents, failed vascular access and inter-
current infectious processes [24]. Renal patients on
dialysis are at risk of cardiovascular disease, due to the link
of oxidative stress and inflammation with endothelial dam-
age and immune system dysfunction and subsequent infec-
tions, perpetuating an oxidation-inflammation-infection
cycle. Furthermore, the effects of the low activation of vita-
min-D receptors are enhanced by the significantly reduced
Table 2 Inflammation markers in serum of patients
before treatment initiation with paricalcitol and after
12 weeks of treatment
Paricalcitol P
valuen Baseline values After 12 weeks
CRP, mg/L 19 21.7 ± 20.7 11.8 ± 10.3 ↓ 0.0076
TNF-α, pg/mL 13 6.15 ± 3.49 3.23 ± 1.96 ↓ 0.012
IL-6, pg/mL 13 8.96 ± 3.84 6.23 ± 1.91 ↓ 0.019
IL-18, pg/mL 13 276 ± 77 199 ± 98 ↓ 0.028
IL-10, pg/mL 13 0.39 ± 0.03 0.428 ± 0.032 ↑ 0.019
IDO*, μM Kyn 19 3.33 ± 1.03 3.01 ± 1.14 0.167
CRP, C-reactive protein; TNF-α, Tumor necrosis factor; IL-6, Interleukin 6; IL-18,
Interleukin 18; IL-10, Interleukin 10; IDO, Indoleamine 2,3-dioxygenase,
measured as kynurenine. Values are given as mean ± SD. Statistical
significance assessed using Wilcoxon Signed Rank Test.
*IDO: intra-assay coefficient of variation = 2.8%, inter-assay coefficient of
variation = 4.8%.
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ney disease (CKD), further contributing to endothelial dys-
function [14,15,25]. These circumstances lead inexorably
to cardiovascular disease, which is a major cause of mortal-
ity in renal patients.
Therapy with vitamin D for hemodialysis patients was
primarily designed to treat SHPT, regulating calcium
and phosphorus absorption in the intestine and bone re-
modeling. This approach showed parallel benefits, as
preclinical in vitro and observational studies found that
treatment with a nonselective vitamin D activator (calci-
triol) also decreased inflammatory markers [26,27] and
had immunomodulatory effects [28], thus showing the
potential to reduce cardiovascular damage and mortality,
beyond the primarily intended control of SHPT [29].
Despite presenting excellent control of SHPT, and add-
ing this anti-inflammatory effect, calcitriol treatment has
the drawback of producing elevated serum phosphorusTable 3 Enzymatic antioxidant activity and oxidation markers
treatment with paricalcitol
n= 19 Paricalcitol
Baseline values After 12 weeks
Antioxidants
SOD, U/g Hb 734 ± 481 1776 ± 574
CAT, U/g Hb 2424 ± 832 3268 ± 1363
GSH, μmol/g Hb 1.79 ± 0.76 2.87 ± 1.24
TRX, ng/mL 60.2 ± 17.0 89.7 ± 22.1
Oxidation markers
MDA, μM 1.14 ± 0.18 0.96 ± 0.14
CG, nmol/mg prot 1.78 ± 0.75 1.16 ± 0.45
Nitrites, μM 7.09 ± 3.42 4.33 ± 3.71
SOD, Superoxide dismutase; CAT, catalase; GSH, reduced glutathione; TRX, Thioredo
mean ± SD. *intra-assay coefficient of variation, **inter-assay coefficient of variationand calcium levels. This effect is caused by increased in-
testinal absorption of both electrolytes [30,31], and lim-
its the usefulness of calcitriol in patients with severe
renal disease, since the calcium and phosphorus over-
load cannot be adequately excreted by a failing kidney.
However, the good clinical results obtained for VDRA
agonists against SHTP and the need to reduce adverse
effects has prompted further research for improved
VDRAs. Therefore, the present study focuses on a sec-
ond generation direct selective VDR agonist, 19-nor-
1,25-dihydroxyvitamin D2, or paricalcitol. This selective
VDRA has already shown improved effects on calcium
homeostasis and SHPT treatment [31-33], controlling
SHPT without increasing serum electrolyte concentra-
tions to the levels induced by calcitriol [34,35]. In our
sample, the beneficial effects on SHPT are clear, and al-
though our patients did experience a significant increase
in calcium and phosphate, the focus of our study was on
other pleiotropic effects that have been reported.
The central findings of this study are the antioxidant
effects of paricalcitol in a clinical setting. Redox homeo-
stasis is a clinical concern in dialysis patients and, al-
though hemodialysis with on-line regeneration of the
ultrafiltrate has shown some improvement over conven-
tional polysulphone dialysis in some parameters [36,37],
the treatment is still related to oxidative stress, and
patients undergoing hemodialysis with any of these tech-
niques may benefit from concomitant treatments that
could contribute to redox homeostasis. The anti-inflam-
matory/antioxidant effect of a VDRA was recently
reported by Wu et al. [26], who carried out a study in
hemodialysis patients with SHPT receiving calcitriol for
16 weeks. Paricalcitol had shown some promise regard-
ing redox homeostasis in preclinical studies. Husain
et al. designed an antioxidant strategy including enala-
pril and paricalcitol for ApoE-deficient atheroscleroticin the blood of dialysis patients before and after
intraCV* interCV** P
value
↑ 4.8 % 3.8 % 0.00005
↑ 2.4 % 4.03 % 0.0056
↑ 4.4 % 5.3 % 0.0002
↑ 2.3 % 3.1 % 0.002
↓ 3.1 % 2.8 % 0.002
↓ 2.7 % 3.3 % 0.0007
↓ 3.8 % 3.4 % 0.01
xin; MDA, malondialdehyde; CG, carbonyl groups; Hb, hemoglobin. Values are
.
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formation of angiotensin II, which is known to induce
free-radical generation. This combination demonstrated
protective efficacy in aortic inflammatory and oxidative
injury in this animal model [38]. Moreover, paricalcitol
has also shown protective effects against oxidative stress
in the cardiac tissue of uremic rats, through inhibition of
NADPH oxidase activity [39], but there was still no clin-
ical evidence of the anti-inflammatory/antioxidant effect
of this selective VDR.
The increased levels of SOD and GSH with paricalcitol
treatment found in our study follow preclinical findings
with this selective VDR agonist. Since both GSH and
SOD are the main contributors to cellular redox homeo-
stasis, it is rather relevant that paricalcitol treatment
seemed to increase the levels of these ROS scavengers,
but we also found increased thioredoxin levels. A recent
study on the effects of VDRAs on the thioredoxin
pathway in endothelial cells in vitro indicated that pari-
calcitol did not modify thioredoxin expression or activ-
ity, although expression of its inhibitor, thioredoxin-
interacting protein, was significantly reduced [40]. How-
ever, in vitro environments are rather limited and the
higher levels of thioredoxin after paricalcitol treatment
found in our study are consistent with the increase in
other components of the antioxidant arm. The induction
pathway of most of these antioxidant molecules by pari-
calcitol remains unknown, and further exploration of
their signaling pathways could provide more information
on the different mechanisms of paricalcitol and calci-
triol, as suggested by their different effects.
Regarding the oxidation markers, the reduction in
MDA levels by paricalcitol was also reported in an ani-
mal model, and it was postulated that the reason could
be downregulation of RAS by vitamin D analogues [38].
The antioxidant effect of paricalcitol is further observed
with the reduction of carbonyl groups and nitrites. The
latter may be due to a previously described downregula-
tion of eNOS and iNOS activity, which would respond
both to an antioxidant and anti-inflammatory effect of
VDR activation [38,41]. On the other hand, the reduced
production of nitrites, MDA and carbonyl groups could
also be a consequence of the increased antioxidant
elements, i.e. GSH, thioredoxin and SOD, scavenging
excess ROS before excessive oxidation can take place.
Modulatory effects on inflammatory and immune sig-
naling pathways in vitro have been previously described,
with significant reduction of proinflammatory cytokines
IL-8, CRP and TNF-α and increased anti-inflammatory
markers [12,42]. As previous studies have suggested, our
results showed significant reduction of several inflamma-
tory markers (CRP, TNF-α, and ILs 6 and 18) in CKD
patients treated with paricalcitol, while IL-10, an anti-
inflammatory cytokine, was significantly increased in theserum of our patients. No significant changes were
found in IDO activity; these results have not been
included in this study because IDO activity and kyneur-
ine are increased in CKD patients and have been linked
to atherosclerosis [43-45]. Permanent hemodialysis
catheters are a well-known source of inflammation, and
our patients had two different types of venous access,
so we checked for differences in inflammatory markers
between the patients with catheters and those with ar-
teriovenous fistula, finding similar baseline and final
results (data not shown), which finally allowed for a
pooled analysis. Our findings are similar to those of
Alborzi et al. [46], who observed a 20% reduction in
CRP with paricalcitol. Navarro et al. [47] also found a
significant reduction in CRP and TNF-α, while detecting
higher levels of TNF-α/IL-10 and IL-6/IL-10 indices,
showing an immunomodulatory effect as suggested by
our own results. Our findings in this group are consist-
ent with previous reports on clinical data and experi-
mental studies in rats [12,42,48].
The results of this clinical study, conducted on 19
patients with hemodialysis, suggest another important
effect of paricalcitol, regarding renal disease complica-
tions. This is the first report on the antioxidant effects
of a VDR agonist, namely the selective agonist paricalci-
tol, in a clinical study involving renal patients. One limi-
tation of this study is the absence of a placebo arm, as
our study was performed in the setting of routine clin-
ical practice and comparison with a control group was
not possible. However, comparison of final values, with
baseline analyses of the same patients acting as control,
showed significant changes after paricalcitrol treatment;
these very significant changes in so many different
parameters are unlikely to be observed in an untreated
control group as a result of spontaneous evolution.
Moreover, these improvements in redox homeostasis
could be observed after a short treatment period of three
months indicating that, although the study period was
very short, three months was also enough to observe sig-
nificant changes. Since this study was conducted in a
clinical setting and the patients were receiving concomi-
tant medication, an association between oxidative stress/
inflammation and other medications commonly adopted
in dialysis patients, such as ACE inhibitors, ARBs or
chelating agents could be suspected [49-51]. However,
the participants’ concomitant medication was started be-
fore the study and maintained without modifications
during the study, so the possible effects of these drugs
were constant. Although the laboratory results of the
three patients who were receiving ACE inhibitors were
well within the range of values obtained for the rest of
the patients, we performed a sensitivity analysis exclud-
ing these patients to determine any influence that this
medication might have in our results, but the level of
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not shown). The main limitations are the small sample
size and the lack of a control group or randomization,
with possible selection bias, since the setting and cir-
cumstances in which it was performed did not allow
improvements in this aspect.
Conclusions
Hemodialysis patients receiving this selective VDR agon-
ist could benefit not only from SHPT control but also
from anti-inflammatory and antioxidant effects that
could improve their situation in terms of cardiovascular
protection. We consider the results of this study promis-
ing, as improvements were seen in a very short follow-
up period, although a larger trial comparing treatment
with paricalcitol, other VDR agonists and placebo could
provide conclusive data on the topic.Competing interests
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